c fms in 9

c-Fms-IN-9 is a c-FMS inhibitor that inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT with IC50 values of <0.01 μM and 0.1-1 μM, respectively.

c-Fms-IN-1 is an inhibitor of c-FMS kinase (IC50 = 0.8 nM).

c-Fms-IN-3 is a novel inhibitor of c-FMS, suitable for research on antirheumatic and anti-inflammatory diseases.

3-(9-Chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)benzeneacetamide inhibits multidrug resistance protein (MRP1).

c-Fms-IN-2 is an inhibitor of c-FMS kinase (IC50 = 24 nM).

c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (IC50 = 17 nM) and serves as an anti-inflammatory agent.

2-Amino-6-chloro-9-(2-C-methyl-β-D-ribofuranosyl)-9H-purine is a 2'-C-Methyl nucleoside; Halo-nucleoside.

2’-C-Methyl nucleoside; 2/6/8-modified nucleoside

CypD inhibitor C-9 is a CypD inhibitor, it attenuates mitochondrial and cellular perturbation insulted by Aß and calcium stress.

6-Chloro-9-(2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-9H-purine is a 2'-C-Methyl nucleoside and a halo-nucleoside.

6-Methoxypurine-9-β-D-5’(R)-C-methylriboside, an analog of hypoxanthine—a purine base predominantly found in muscle tissue and a metabolite generated when purine oxidase acts on xanthine—displays anti-inflammatory properties and functions as a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. Its cytoprotective role is underscored by its ability to inhibit PARP activity, thus preventing peroxynitrite-induced mitochondrial depolarization and subsequent superoxide production. Furthermore, hypoxanthine serves as a biomarker for hypoxia [1] [2].

c-Met-IN-9 is a 4-phenoxypyridine derivative and a c-Met kinase inhibitor (IC50: 12 nM). c-Met-IN-9 induces apoptosis and shows antitumour effects.

9-(5(R)-C-Methyl-2,3,5-tri-O-benzoyl-b-D-ribofuranosyl)-6-chloropurine is a useful organic compound for research related to life sciences and the catalog number is TNU0992.

c-Myc Inhibitor 9 (Compound 332) is an effective c-Myc inhibitor, exhibiting a logEC50 of ≥6, and demonstrating significant tumor growth inhibition in nude mouse models. This compound is utilized in cancer research.

c-Fms-IN-12 is an FMS kinase inhibitor that also inhibits c-KIT and induces apoptosis in A549 cells. c-Fms-IN-12 is a potential broad-spectrum anti-cancer agent that has demonstrated therapeutic effects in a variety of cancer types.

c-Fms-IN-14 (Example 76) is a potent c-Fms kinase inhibitor with an IC50 of 4 nM, used in cancer and autoimmune disease research [1].

c-Fms-IN-6 is a potent inhibitor of c-FMS (IC50 ≤10 nM for unphosphorylated c-FMS) and weakly inhibits unphosphorylated c-KIT and PDGFR (IC50: >1 μM).

2-Amino-6-chloro-9-[(2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)]-9H-purine is a 2'-C-Methyl nucleoside and a Halo-nucleoside.

9-(2-C-methyl-2,3,5-tri-O-benzoyl -β-D-ribofuranosyl) purine is a 2'-C-Methyl nucleoside; 6-De-aminopurine nucleoside.

(1'R,3a'R,8a'S,9'S,9a'S)-1'-Methyl-3'-oxo-N,N-diphenyl-3',3a',5',7',8',8a',9',9a'-octahydro-1'H-spiro[[1,3]dioxolane-2,6'-naphtho[2,3-c]furan]-9'-carboxamide is a useful organic compound for research related to life sciences. The catalog number is T67324 and the CAS number is 900160-98-7.

C-HEGA-9 is a useful organic compound for research related to life sciences. The catalog number is TF0101 and the CAS number is 864434-14-0.

6-Mthoxy-9-beta-D-(2-C-ethynyl-ribofuranosyl)purine is a Nucleoside Derivative - 6-Modified purine nucleoside, 2'-Modified nucleoside.

9-(2,5-Di-O-benzoyl-2-C-beta-ethynyl-beta-D-ribofuranosyl)-6-chloropurine is a useful organic compound for research related to life sciences and the catalog number is TNU1616.

2,6-Dichloro-9-(2-C-methyl-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine is a 2'-C-Methyl nucleoside; Halo-nucleoside.

c-Fms-IN-7 is a cFMS inhibitor with an IC50 of 18.5 nM.

2-Amino-9-(2-C-methyl-β-D-ribofuranosyl)-9H-purine is a 2'-C-Methyl nucleoside; 6-De-aminopurine nucleoside.

6-Ethoxy-9-beta-D-(2-C-methyl-ribofuranosyl)purine is a nucleoside derivative, specifically a 6-modified purine nucleoside and a 2'-modified nucleoside.

9-(5(R)-C-Methyl-2,3,5-tri-O-benzoyl-D-ribofuranosyl)-6-chloropurine, a purine nucleoside analog, demonstrates broad antitumor activity, particularly against indolent lymphoid malignancies, through inhibition of DNA synthesis and induction of apoptosis. [1]

6-Methoxy-9-beta-D-(2-C-ethynyl-ribofuranosyl) purine is a purine nucleoside analog with broad antitumor activity targeting indolent lymphoid malignancies. Its anticancer mechanisms include inhibition of DNA synthesis and induction of apoptosis [1].

c-Fms-IN-10, a derivative of thieno [3,2-d] pyrimidine, is a kinase inhibitor of FMS (Colony-stimulating factor-1 receptor, CSF-1R; IC50: 2 nM) with anti-tumor activity.

9-(2-C-methyl-β-D-ribofuranosyl)purine is a 2'-C-Methyl nucleoside; 6-De-aminopurine nucleoside.

c-Fms-IN-8 is a colony-stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor (IC50: 9.1 nM). It is compound 4a in the reference.

2-Amino-9-[(2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)]-9H-purine is a 2'-C-Methyl nucleoside; 6-De-aminopurine nucleoside.

2’-C-Methyl nucleoside; 2/6/8- modified nucleoside

OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel growth (angiogenesis) in tumors.